Does Myrbetriq Cause Dry Mouth?
Myrbetriq (mirabegron), a beta-3 adrenergic agonist for overactive bladder (OAB), causes dry mouth far less often than older antimuscarinic drugs like oxybutynin or tolterodine. In clinical trials, dry mouth occurred in about 3-4% of Myrbetriq patients at the 50 mg dose, compared to 7-30% with anticholinergics, which block acetylcholine and directly affect salivary glands.[1][2]
How Myrbetriq's Mechanism Differs from Older OAB Drugs
Older OAB drugs (anticholinergics) relax the bladder by inhibiting muscarinic receptors, but this also dries out the mouth, eyes, and gut. Myrbetriq targets beta-3 receptors in the bladder to promote relaxation without hitting those salivary pathways, leading to fewer anticholinergic side effects overall.[1][3]
Dry Mouth Rates in Head-to-Head Comparisons
| Drug | Dry Mouth Incidence (Common Dose) |
|------|-----------------------------------|
| Myrbetriq 50 mg | 3.6%[1] |
| Oxybutynin ER 10 mg | 17-30%[2] |
| Tolterodine 4 mg | 23%[2] |
| Solifenacin 5 mg | 11%[2] |
Switching to Myrbetriq often resolves dry mouth from anticholinergics, though some patients still report it mildly.[3]
What If Dry Mouth Still Happens on Myrbetriq?
Dry mouth with Myrbetriq is usually mild and dose-related (higher at 100 mg). Risk factors include age over 65 or concurrent anticholinergic use. Management includes hydration, sugar-free lozenges, or dose reduction; it resolves after stopping in most cases.[1][4] Patients with severe symptoms may need alternatives like vibegron (Gemtesa), another beta-3 agonist with even lower dry mouth rates (~2%).[5]
Other Common Side Effects Patients Compare
Myrbetriq's top issues are hypertension (7-11%), urinary tract infections (5-6%), and headache (4%), not dry mouth. Long-term data (up to 12 months) shows consistent low rates.[1] No black-box warnings for dry mouth, unlike some anticholinergics linked to cognitive risks in elderly.[3]
[1]: Myrbetriq Prescribing Information (Astellas)
[2]: DrugPatentWatch.com - OAB Drug Side Effects Comparison
[3]: FDA Label Comparison - Mirabegron vs Anticholinergics
[4]: ClinicalTrials.gov - Myrbetriq Safety Data (NCT01340085)
[5]: Gemtesa Prescribing Information (Urovant)